Related Experiment Video
Updated: May 12, 2026
07:08
Fractionation for Resolution of Soluble and Insoluble Huntingtin Species
Published on: February 27, 2018
Targeting sirtuin-1 in Huntington's disease: rationale and current status
1Division of Neurobiology, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, CMSC 8-121, 600 North Wolfe Street, Baltimore, MD 21287, USA. wduan2@jhmi.edu
CNS Drugs
|April 4, 2013
Summary
Sirtuin-1 (SIRT1) shows promise for Huntington's disease (HD) treatment by protecting neurons. Targeting SIRT1 offers a potential therapeutic strategy for this neurodegenerative disorder.
Area of Science:
- Neuroscience
- Genetics
- Pharmacology
Background:
- Huntington's disease (HD) is an inherited neurodegenerative disorder caused by a huntingtin gene mutation.
- Current treatments for HD are not disease-modifying, highlighting the need for new therapeutic strategies.
- Sirtuin-1 (SIRT1) is a protein deacetylase implicated in longevity and neuroprotection.
Purpose of the Study:
- To review recent advancements in sirtuin-1 (SIRT1) research concerning Huntington's disease (HD).
- To evaluate SIRT1's specificity and potential as a therapeutic target for HD.
- To discuss challenges in developing clinical applications for SIRT1 modulators.
Main Methods:
- Literature review of studies investigating SIRT1 in various animal models of Huntington's disease (HD).
- Analysis of the neuroprotective mechanisms associated with SIRT1's deacetylase activity.
- Examination of existing research on pharmacological interventions targeting SIRT1.
Main Results:
- SIRT1 demonstrates neuroprotective effects in mouse and Caenorhabditis elegans models of HD.
- Evidence suggests a link between SIRT1's deacetylase function and neuronal protection.
- Controversial findings exist in certain models, such as the fly model.
Conclusions:
- SIRT1 represents a promising therapeutic target for Huntington's disease (HD).
- Pharmacological targeting of SIRT1 could offer disease-modifying strategies for HD.
- Further research is needed to overcome challenges in developing clinical SIRT1 modulators for HD treatment.
Related Concept Videos
01:21Huntington Disease l: Introduction
Huntington disease or HD is a progressive, fatal neurodegenerative disorder inherited in an autosomal dominant pattern.PathophysiologyIt is caused by expansion of the CAG trinucleotide repeat in the HTT gene on chromosome 4 (4p16.3), producing an abnormal huntingtin protein with an expanded polyglutamine tract. This misfolded protein disrupts cellular function, leading to neuronal death. Normal alleles have ≤26 repeats, 27–35 are intermediate (risk of expansion), 36–39 show reduced penetrance,...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:30siRNA - Small Interfering RNAs
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...